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Abstract
Background: Giant Axonal Neuropathy (GAN) is a fatal neurodegenerative disorder with early onset characterized
by a severe deterioration of the peripheral and central nervous system, involving both the motor and the sensory
tracts and leading to ataxia, speech defect and intellectual disabilities. The broad deterioration of the nervous
system is accompanied by a generalized disorganization of the intermediate filaments, including neurofilaments in
neurons, but the implication of this defect in disease onset or progression remains unknown. The identification of
gigaxonin, the substrate adaptor of an E3 ubiquitin ligase, as the defective protein in GAN allows us to now
investigate the crucial role of the gigaxonin-E3 ligase in sustaining neuronal and intermediate filament integrity. To
study the mechanisms controlled by gigaxonin in these processes and to provide a relevant model to test the
therapeutic approaches under development for GAN, we generated a Gigaxonin-null mouse by gene targeting.
Results: We investigated for the first time in Gigaxonin-null mice the deterioration of the motor and sensory
functions over time as well as the spatial disorganization of neurofilaments. We showed that gigaxonin depletion
in mice induces mild but persistent motor deficits starting at 60 weeks of age in the 129/SvJ-genetic background,
while sensory deficits were demonstrated in C57BL/6 animals. In our hands, another gigaxonin-null mouse did not
display the early and severe motor deficits reported previously. No apparent neurodegeneration was observed in
our knock-out mice, but dysregulation of neurofilaments in proximal and distal axons was massive. Indeed,
neurofilaments were not only more abundant but they also showed the abnormal increase in diameter and
misorientation that are characteristics of the human pathology.
Conclusions: Together, our results show that gigaxonin depletion in mice induces mild motor and sensory deficits
but recapitulates the severe neurofilament dysregulation seen in patients. Our model will allow investigation of the
role of the gigaxonin-E3 ligase in organizing neurofilaments and may prove useful in understanding the
pathological processes engaged in other neurodegenerative disorders characterized by accumulation of
neurofilaments and dysfunction of the Ubiquitin Proteasome System, such as Amyotrophic Lateral Sclerosis,
Huntington’s, Alzheimer’s and Parkinson’s diseases.
Background
Giant Axonal Neuropathy (GAN) is a severe neurodegen-
erative disorder with early onset and a fatal outcome in
young adults [1,2]. The gait instability in infancy is soon
followed by a wide deterioration of the peripheral
nervous system, affecting both the sensory and motor
tracts. Indeed, patients experience diminution of deep
tendon reflexes often leading to areflexia and a loss of
the deep and superficial sensitivity. The motor deficits
encompass amyotrophy, muscle weakness and evolve
with skeletal deformations and loss of ambulation by the
adolescence. The disease progresses with the deteriora-
tion of the central nervous system, causing ataxia, speech
defect and mental retardation [3]. Defined as an axonal
neuropathy by electrophysiological examination, GAN
induces an axonal loss both in peripheral nerves and in
the brain that is associated with the presence of enlarged
axons, also called giant axons [1,2,4,5]. Strikingly,
enlarged axons are filled with abnormally packed neurofi-
laments (NFs) that lack the proper orientation along the
axon, are increased in diameter and show decreased spa-
cing [4,6]. Whereas NFs are altered in many neurodegen-
erative disorders including Amyotrophic Lateral Sclerosis
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(ALS), Parkinson’s, Alzheimer’s and Charcot-Marie-
Tooth diseases [7], the generalized aggregation of other
neuronal and non neuronal Intermediate Filaments (IFs)
[8,9] in GAN points to a central role of the GAN gene in
maintaining cytoskeletal architecture. In particular, we
used the primary fibroblasts derived from skin biopsies of
multiple patients to show that vimentin aggregation is
greatly enhanced in conditions driving quiescence and is
not caused by an abnormal accumulation of the tubulin
chaperone TBCB and its effect on microtubule stability
[10,11]. After the identification of the GAN gene, encod-
ing for a new BTB-Kelch protein we named gigaxonin
[12], we and others mapped a total of 47 distinct muta-
tions along the entire GAN gene in patients [12-23]. By
revealing a high instability of gigaxonin in multiple
lymphoblasts cell lines from unrelated patients [11], we
confirmed that GAN is caused by a loss of function of
gigaxonin.
The broad impairment of the nervous system and the
generalized disorganization of IFs in GAN emphasize the
crucial role of gigaxonin in maintaining neuronal and IF
integrity. Moreover, gigaxonin was shown to be a direct
key player in the Ubiquitin Proteasome System (UPS), as
parkin in Autosomal Recessive Juvenile Parkinsonism
(AR-JP) [24]. Indeed, BTB-containing proteins, including
gigaxonin have been found to be the substrate adaptors
of Cul3-dependant E3 ubiquitin ligases, interacting with
Cul3 and the substrates through the BTB and the
C-terminal domains, respectively [25-27]. The UPS is
impaired in more common disorders such as ALS, Alz-
heimer’s, Parkinson’s and Huntington’s diseases, but the
study of its contribution to the pathology is complicated
by its indirect role. Thus gigaxonin provides us with an
opportunity to address directly the role of the UPS in
neurodegeneration. Gigaxonin was shown to regulate
in vitro the abundance of its three known substrates, the
Microtubule (MT)-Associated Proteins MAP1B, MAP1S
and the tubulin chaperone TBCB, through ubiquitin-
mediated degradation by the proteasome [28-30]. Never-
theless, the modest implication of these substrates in the
survival of GAN-/- cortical neurons [28,29] and vimentin
aggregation in patients fibroblasts [11] suggests that the
mechanisms by which the gigaxonin-associated E3 ligase
promotes neuronal survival and IF integrity remain to be
elucidated.
In order to study the role of gigaxonin in these pro-
cesses, and to evaluate the efficacy of GAN treatments
that are currently under development, a relevant GAN
animal model is essential. We and others independently
disrupted the murine GAN gene in exons 3-5 (∆ex3-5)
[29] or promotor-exon1 (∆ex1) [31] to generate gigaxo-
nin-null mice. Whereas both published studies agree on
the alteration of IFs in the nervous system of GAN-/-
mice, there is an important controversy concerning the
degree of severity of the disease. Indeed, the GAN∆ex1
mouse did not develop overt neurological deficits over
15 months, suggesting a milder form of the disease in
mice [31]. On the contrary, the published GAN∆ex3-5
model (referred here as GANYY) was reported to
develop strong motor deficits as early as 6 months of
age, including reduction of spontaneous movement,
bizarre limb positioning and overall weakness [29]. In
order to characterize more precisely the phenotype of
GAN-/- mice, we conducted the first behavioral analysis
over a 72-week period in our own GAN∆ex3-5 model,
generated in parallel to the other studies. Monitoring of
motor and sensory functions showed a mild but persis-
tent motor impairment from 60 weeks in the 129/SvJ
genetic background, while C57BL/6 animals displayed
rather a deterioration of sensory functions. We tested
motor deficits in the GANYY mice in parallel, and the
absence of clinical signs within the first year in our
hands is in agreement with a mild progression of the
disease in mice, indicating that the three existing models
probably display a phenotype of similar intensity.
Despite the modest phenotypic manifestation and no
pronounced signs of neurodegeneration, our GANex3-5
mice exhibited severe cytoskeletal alterations. Indeed,
we show here an increase in the diameter of NFs and an
overt impairment in their orientation, consistent with
the human disease. In addition, we found that this
alteration in NF spatial organization is accompanied by
a strikingly increased abundance of the three NF sub-
units. We also show here that gigaxonin is preferentially
expressed in neuronal tissues and during development.
Altogether, our results show that the absence of gigaxo-
nin results in a milder version of the GAN disease in
mice at the behavioral level, associated with a severe dis-
organization of the NF network that recapitulates what
is observed in patients.
Materials and methods
Generation of GAN-deficient mice
A probe containing the murine GAN exons 4-5 was
used to screen a BAC/PAC library (RPCI-22, Oakland,
CA, http://bacpac.chori.org/libraries.php?disp=c). For
the GAN targeting vector, 1.7 kb SspI-XmaI and 6.2 kb
BsaWI-HindIII genomic DNA fragments homologous to
5’ and 3’ fragments of the mouse GAN gene were cloned
using PGK-neo and diphteria toxin for selection. ES
cells, electroporated with the linearized vector were
selected with 250 μg/ml G418. One surviving clone
among 400, correctly targeted accordingly to Southern
blotting, was injected into C57BL/6 blastocysts to gener-
ate chimeras. Successive backcrossing of the F1 GAN+/-
with commercial C57BL/6 and 129/SvJ mice generated
pure C57BL/6 (98,4%) and 129/SvJ (100%) GAN mice,
that were interbread to obtain GAN+/+, GAN+/- and
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GAN-/- littermates. Animals were treated in accordance
with the European Union guide for the care and the use
of animals in research (commission June 18th 2007,
2007/526/CE). Genotyping was performed by polymer-
ase chain reaction using three primers: the targeted frag-
ment (600 bp) was amplified by the 5’neo (TGC GAG
GCC AGA GGC CAC TTG TGT AGC) and 3’GAN pri-
mers (ATG CCA TGG ACC ATG TAT GAA GGT),
and the WT fragment (700 bp) by 5’GAN (TGC CTT
CCT GTC TTC CTT ATC CAC) and 3’ GAN primers.
Behavioral assay
Behavioral analysis was performed over a 72-week-period
on littermate GAN+/+, GAN+/- and GAN-/- mice (15
mice per genotype, for both C57BL/6 and 129/SvJ back-
grounds). All tests were performed every 4 weeks from
24 weeks of age with the appropriate devices (Bioseb,
France). For Grip strength measurement, mice were
allowed to grip a horizontal bar, and pulled until they
released (5 trials for fore- and hind-limbs). For Rotarod
analysis, mice were first trained to stay for 2 min on a bar
rotating at 9 rpm. Mice were then placed on the rotating
rod automatically accelerating from 4 rpm to 40 rpm for
5 min; the latency of the time to fall was recorded in 3
successive trials. In the Von Frey test, mice were first iso-
lated in wire-mesh floor cages for 1 h. Then, the plantar
surface of the hind limbs was stimulated with a set of
calibrated monofilaments (3 trials per monofilament)
with increasing force until the mice withdrew the limb.
The minimum intensity of mechanical stimuli was taken
as the force at which the mouse withdrew the paw. For
the Hot plate test, mice were placed on a metal surface
maintained at 53°C and the response latency to shouting,
shaking, jumping or licking the hind limbs paws was
measured 3 times with a 15-min interval (cut-off time:
30 sec). For the Foot print test, hind and fronts paws
were painted with non-toxic finger red and blue paints.
Mice then walked in a restricted cardboard tunnel with a
white-paper-covered floor, and measures were taken on a
sequence of 6 consecutive steps.
Tissue preparation and morphological analysis
Mice were perfused transcardially with 4% paraformalde-
hyde (PFA) buffer pH 7.4 (Antigenfix, Diapath). Tissues
were post-fixed O/N in 4% PFA (4°C), kept for 2 days in
PBS 30% sucrose before embedding with Optimal Cut-
ting Temperature (OCT) and kept at -80°C. For electron
microscopy, tissues were kept overnight in modified Kar-
novsky’s fixative containing 2.5% glutaraldehyde, 2.0%
paraformaldehyde, 0.1% tannic acid in 0.1 M cacodylate
buffer pH 7.3, post fixed 1H in 1% osmium tetroxyde
then dehydrated in ethanol and finally embedded in
epon. For counting motor neurons, 17 μm sections of
lumbar spinal cords were cryosectionned, mounted onto
slides and immunostained with anti-VaCHT antibody
(SIGMA; 1:2500). Only motor neurons with a distinct
absence of staining in the nucleus were counted. Sections
of sciatic and L5-roots (0,5 μm) were stained with 1%
toluidine blue and axons were counted manually, and
normalized with the area of the nerve determined by the
ImageJ software. For cytoskeletal architecture, digital
electron images of ultra thin sections (80 nm) were taken
with a ZEISS EM 912 microscope. The quantification of
the alteration of NFs was performed by Image J, using a
plug-in designed by Dr C. Matthews. The number of
MTs was counted manually.
Western blot analyses
Immunoblotting of proteins extracted from tissues was
performed as described in [11]. Tissues from the
GANex1 and the GANYY mice were generously provided
by Pr Julien and Dr Yang, respectively. Antibodies:
mouse anti-gigaxonin [11] (N12, 1:150), rabbit anti-
MAP1B-LC and anti-MAP1S-HC (kind gift from Pr
Propst, 1:500), mouse anti-TBCB (AbnovaH00001155-
A01, 1:250), mouse anti-NFL (Millipore MAP1615,
1:250), mouse anti- NFH (Millipore MAB5266, 1:200),
mouse anti-NFM (Millipore MAB5254, 1:500), mouse
anti-ßactin (Abcam 8226, 1:1000), mouse anti-GAPDH
(Ambion 4300, 1:4000). Quantifications were performed
with Image J after normalization with GAPDH/actin.
Results
Generation of the GANex3-5 mice
The GAN-deficient mouse was obtained by homologous
recombination in the GAN locus in mouse ES cells. To
avoid events of exon skipping within the GAN gene, exon
2 was not targeted because it could possibly have pro-
duced an in-frame transcript containing exons 1, 5 to 11
encoding for a full C-terminal Kelch domain. The repla-
cement of exons 3 to 5 by a neomycin resistance gene
generated a premature stop codon in exon 6, producing a
truncated protein of 12 kDa, lacking a portion of the
BTB domain and the entire Kelch domain (Figure 1A).
The screening of ES clones performed by Southern blot-
ting allowed the identification of homologous recombina-
tion in one single clone (Figure 1C, ES lane) that was
used to generate GAN ex3-5 mice. The deletion of the
GAN exons 3-5 was further confirmed in GAN Het and
KO mice by the polymerase chain reaction and by South-
ern blotting (Figure 1B, C). Immunoblotting showed no
detectable full-length gigaxonin in KO brain lysates, con-
firming the disruption of the GAN gene (Figure 1D).
Preferential expression of gigaxonin during
embryogenesis in neuronal tissues
Monoclonal antibodies, previously developed to reveal
gigaxonin’s low abundance in brain [11], were used to
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assess its spatio-temporal expression in different mouse
tissues. Gigaxonin was expressed evenly throughout the
nervous system but with very low levels of expression in
muscle, heart, kidney and liver (Figure 2A-C). Its tem-
poral expression, assessed in brain and lumbar section
of spinal cord from embryonic stage E15 to 6 months of
age, revealed that the high levels of gigaxonin detected
in embryonic stages up to PO, dropped by 50-56% in
both tissues after birth, and then stayed constant in
adults.
GANex3-5 mice show mild motor and sensory
impairments
Considering the massive deterioration of the sensory-
motor functions in patients [1,2], leading to loss of
ambulation and to the loss of the deep and superficial
Figure 1 Construction of the GAN-/- mouse. (A) Schematic representation of the disruption of the GAN gene. The targeted construct was
designed to replace the endogenous exons 3-5 GAN locus with a neomycin-resistant gene (neo R). The diphteria toxin gene, placed at the 3’
end of the targeting vector allowed positive selection for the homologous recombination at the GAN locus. Proper targeting produces an open
reading frame of only 110 amino acids terminated by a premature stop codon in exon 6. The ∆ GAN locus will only produce a ∆ gigaxonin of
12 kDa, possibly unstable and entirely lacking the Kelch domain and a portion of the BTB domain. (B, C) Analysis of the genomic DNA from Wild
Type (WT), heterozygous (Het) and GAN knock out mice (KO) by polymerase chain reaction (PCR) (B) and Southern blot after BglII digestion (C).
The Embryonic Stem cell (ES) corresponds to the original GAN targeted clone. (D) Brain extracts (50 μg) from WT and GAN knock out mouse,
and COS cell lysates (cosT; 0,5 μg) transfected with WT-gigaxonin were analysed by immunoblot using anti-Gigaxonin antibody.
Figure 2 Preferential expression of gigaxonin in neuronal tissues. Protein extracts (50 μg) of neuronal (A) and non neuronal (B) tissues from
24 week-old WT and GAN KO mice were immunoblotted with anti-gigaxonin (GigA) and anti-Actin antibodies. Cereb. = cerebellum; Sc. (C) =
cervical section of spinal cord; Sc. (L) = lumbar section of spinal cord; SN = sciatic nerve. Specificity of detection is demonstrated by the absence
of immunoreactivity in the tissues from KO mice. Note that the abundance of actin (comparable between WT and KO mice) varies in non
neuronal tissues. The relative abundance of gigaxonin in multiple tissues was assessed by immunoblotting with GigA antibody (C, top panel).
Coomassie blue staining indicates the equal loading of total proteins in all the tissues (C, bottom panel). (D) Temporal expression of gigaxonin,
from embryonic stage E15 to adult stage (6 months) was determined in brain and lumbar sections of WT mice by immunoblotting with GigA,
and normalized with anti-GAPDH antibody (n = 3; Mann-Whitney test, *, p < 0.05; bars represent standard deviation).
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sensitivity, we investigated the progression of the disease
in gigaxonin-depleted mice over time.
Thus, we conducted the first behavioral study on
GAN mice over a 72-week period using motor and sen-
sory tests, on a homogeneous cohort of GANex3-5 mice
in the original pure 129/SvJ background.
At 72 weeks of age, GANex3-5 mice displayed a specific
impairment in the Grip strength in the forelimbs, with
mean values of 110 ± 8,68 and 109,58 ± 8,26, respec-
tively, for the WT and Het mice and of 99,15 ± 7,48 for
KO mice (Figure 3A). This motor deficit is mild com-
pared to humans but persists over 4 consecutive
Figure 3 GAN mice present persistent motor deficits. Motor functions were evaluated with a Grip Strength test (A), and a Rotarod test (B).
Sensory deficits were recorded with a Hot plate test (C) and Von Frey filaments test (D). Each test was performed every 4 weeks over a 72
week-period (n = 15 mice per genotype). The scores of individual mice are represented at 72 weeks with the mean score represented by a bar
for each genotype. The average score was also represented over time for the Forelimb grip test, to show the statistical significance of motor
impairment in the GAN mice from 60 weeks of age (two-way ANOVA with Bonferroni post-test: *, p < 0,5; **, p < 0,01 and ***, p < 0,001). Gait
analysis of the GAN mice at 72 weeks of age (E). The stride length (i), the width between the right and left paws (ii) and the overlap between
the forepaws and hindpaws was measured for each mouse (n = 15 per genotype) and averaged (bar). Analysis of the other GANex3-5 model
(GAN YY) did not reveal any motor deficits within the first year of age (F) (n = 10 per genotype).
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months, starting at week 60 (Figure 3A, right panel).
Analysis of the motor activity of GANex3-5 mice by the
Rotarod test showed no significant difference between
WT and gig-null mice, although the last data set (week
72) showed a strong tendency towards a decline for KO
mice (Figure 3B). We did not detect significant changes
in the average sensitivity to temperature in GANex3-5
mice over the 72-week period (Figure 3C), although a
single KO mouse developed a strong insensitivity over
the last five consecutive months. Sensitivity to mechani-
cal stimuli was not impaired in GANex3-5 mice, as the
retraction of paws upon filaments pressure did not sig-
nificantly differ between WT and KO mice during the
entire study (Figure 3D).
As cerebellar functions are impaired in GAN patients,
we recorded the gait of GANex3-5 mice using a footprint
test (Figure 3E). Measurements of the stride length, the
width between left and right paws and the overlap
between fore and hind paws at 72 weeks of age did not
reveal any differences between the WT, Het and KO mice
that performed the test. However, 34% of the KO mice
and 14% of the Het mice that were otherwise moving nor-
mally could not be evaluated due to abnormal pausing or
refractory behavior to enter in the tunnel. Finally, neither
animal weight nor viability was affected by gigaxonin
depletion over the 72-week period (data not shown).
To assess for a possible phenotypical variability in dif-
ferent genetic backgrounds, we performed a similar
behavioral study in GANex3-5 mice derived in a 98,4%
pure C57BL/6 background at 24, 48 and 72 weeks of
age. Interestingly, we revealed a mild sensory deficit in
the GANex3-5 mice in this line, but no effect on motor
abilities. Indeed, C57BL/6 GANex3-5 mice were signifi-
cantly less sensitive to heat, with a mean time spent on
the hot plate of 10,40 ± 5,41; 9,43 ± 5,52 for the WT
mice and 15,95 ± 5,66; 15,41 ± 5,92 for the KO mice at
48 and 60 weeks of age, respectively (Additional file 1).
Three of the KO mice developed the highest insensitiv-
ity from 48 weeks of age, with individual times repeat-
edly approaching the time cut limit. Gait, animal weight
and survival were not compromised in C57BL/6
GANex3-5 mice.
Another GAN model (GANYY) with deletion of exons
3 to 5 in the GAN gene was reported to develop a pro-
gressive and severe deterioration of motor functions
from 6 months of age [29]. In this study, GANYY mice
displayed a reduction of spontaneous movements,
bizarre limb positioning and overall weakness, followed
by muscle wasting and weight loss. To assess for a pos-
sible phenotypic difference between the two GANex3-5
models, we performed the same motor behavioral tests
used for our model on GANYY mice. In our hands,
GANYY mice do not show any motor deficits over a 52
week-period, as revealed by normal grip strength
measurements and unaltered motor activity on the
Rotarod test (Figure 3F). Difficulty in walking, fragile
hair or absence of whiskers, previously reported in the
GANYY model [29], were occasionally observed in con-
trol mice and at a similar and normal frequency in both
GAN models (GANYY and GANex3-5) (data not shown).
Lastly, in our hands GANYY mice did not display any
abnormal weight loss compared to the controls over the
course of the experiment (data not show).
Preservation of lumbar motor neurons and axons in
GANex3-5 mice
To assess whether gigaxonin ablation produces, as in
humans, a neuronal loss in the ventral horn of the
spinal cord [32], a decrease of axonal density in periph-
eral nerves and a presence of giant axons [4,5], we
examined cross sections of spinal cords and proximal/
distal nerves from 48 week-old GANex3-5 mice. Regard-
less of the genetic background, the number of motor
neurons in lumbar spinal cord did not differ between
WT and KO mice (Figure 4A and Additional file 2).
Similar experiment performed at 72 weeks did not
reveal any significant motor neurons loss in 129/SvJ
GANex3-5 mice (data not shown). The counting of axo-
nal content, distally in the sciatic nerve and proximally
in the ventral and dorsal roots of lumbar sections L5
showed a constant tendency towards a decrease in axo-
nal density in the original 129/SvJ background but not
in the C57BL/6 background (Figure 4B, C and Addi-
tional file 2). No giant axons were observed in any of
these tissues.
Severe alteration of cytoskeletal architecture in GANex3-5
mice
In human, GAN induces a profound alteration of IF
architecture. Inside the nervous system, the organization
of NFs is severely impaired: they exhibit an abnormal
compaction, an alteration in longitudinal orientation
and an increase in diameter [4,6]. To evaluate the effect
of gigaxonin depletion on cytoskeletal architecture in
mice, we conducted an ultrastructural analysis of proxi-
mal and distal nerves in our GANex3-5 mouse model.
This revealed a profound impairment in cytoskeletal
organization in GANex3-5 mice at 48 weeks of age, and
in both 129/SvJ and C57BL/6 backgrounds (Figure 5
and Additional file 3).
In the 129/SvJ mice, the axoplasms of GANex3-5 pre-
sent a 6,25-, 2,9- and 4-fold decrease in the number of
microtubules in sciatic nerves, L5-ventral and dorsal
roots, respectively (Figure 5A, B). In the absence of giga-
xonin, NFs are abnormally distributed and lose their
regular and parallel orientation along the axons, display-
ing either mixed populations of well-oriented and mis-
oriented NFs or completely disorganized NFs (Figure
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5A). This alteration in NF orientation was quantified by
measuring the circularity (CIRC) of the sections of indi-
vidual NFs on micrographs. The mean CIRC values, for
which the highest possible value of 1 represents an
orientation of all NFs perfectly parallel to the axon,
were found to be significantly lower in gigaxonin-null
tissues than in controls (sciatic: WT = 0,62 ± 0,003;
KO- = 0,52 ± 0,006, L5-ventral root: WT = 0,62 ±
0,003; KO- = 0,55 ± 0,03. Figure 5C, left panels).
Furthermore, the standard deviation of the CIRC scores
within each image, a measure that is indicative of differ-
ences of orientation of individual NFs within a given
axon, was significantly higher in the GAN mice than in
the controls (Figure 5C, right panels). In addition, we
showed that the diameter of the properly orientated NFs
significantly increased in GANex3-5 axoplasms, from 8,77
± 0,08 nm for the controls to 12,76 ± 0,22 nm; 9,00 ±
0,46 nm to 10,68 ± 0,21 nm; 8,96 ± 0,40 nm to 10,57 ±
0,36 nm in GANex3-5 sciatic, L5-ventral and dorsal
roots, respectively (Figure 5D).
We revealed a similar alteration of MT content, NF
orientation and diameter in C57BL/6 GANex3-5 mice
(Additional file 3).
Profound alteration of NF protein levels in GAN models
To assess whether the impaired distribution of NFs is
associated with an increased abundance of NF proteins,
we quantified the expression level of the three subunits
NF-L, NF-M and NF-H in mouse brain, spinal cord and
sciatic nerves, in the three gigaxonin-null mice: (our
GANex3-5 mouse, the GANYY and the GANex1 mice).
The analysis revealed an increased abundance of
all three NF subunits, in all tissues and at all ages
(Figure 6A, C). For all three NF subunits the maximum
increase, ranging from 2-3 fold, was detected in brain
tissues, with 1,5-2,5 fold increases in spinal cord and
sciatic nerves. Interestingly, whereas the overabundance
of NF-M and NF-H is constant overall from 24 to
48 weeks of age, a spectacular increase of NF-L is
observed at 48 weeks of age specifically in the brain (Fig-
ure 6A, C). Indeed, the abundance of NF-L is increased
4,3- to 6,7- fold in the brain of the three GAN models.
Finally, we determined the expression levels of gigaxo-
nin’s known partners MAP1B, MAP1S and TBCB, that
were shown to be increased 1.5- to 3-fold for MAP1B/
MAP1S and much higher for TBCB in GANYY mice
[28-30]. Our analysis confirmed a less than 2-fold
increase of MAP1S in GAN brain, while in our hands
the level of TBCB was only increased by less than 3-fold
compared to controls, and MAP1B abundance was not
significantly affected, in all three murine GAN models
and at both ages tested (Figure 6B, C).
Discussion
This report of the behavioral analysis on aging mice dis-
rupted in the GAN gene evaluates for the first time the
deterioration of motor and sensory functions, both of
which are impaired in human GAN. Our analysis reveals
a late onset but robust motor impairment over time,
affecting preferentially the grip strength in the forelimbs
from 60 weeks of age in a pure 129/SvJ background. The
fact that a single mouse showed a persistent decrease in
sensitivity to thermal stimulus might also suggest a possi-
ble very low penetrance of sensory dysfunction. Sensory
deficits developed over time in the C57BL/6 GAN ani-
mals that in turn displayed no motor deficits, which may
indicate a modulation of the phenotype by the genetic
background. Our results are in agreement with the
absence of weakness in the hind limbs monitored over
15 months in another GAN model (GANex1) [31]. In our
Figure 4 Lumbar motor neurons and axons are preserved in
GAN mice. (A) Cross sections of lumbar spinal cord from 48-week-
old WT and GAN mice, stained with VaCht (n = 4 animals). Inserts
show lower magnification. (B-C) Cross sections of sciatic nerve (B),
L5 dorsal and ventral roots (C) from 48-week-old WT and GAN mice,
stained with toluidine blue. The numbers of distal axons (B),
proximal motor and sensory axons (C) are represented for each
mouse (n = 4 per genotype) and averaged (bar). Bars = 50 μm (A,
B, C).
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hands, no motor deficits were observed in the first year of
life in the third GAN model (GANYY) [29], previously
reported to develop a progressive and strong deteriora-
tion of motor functions from 6 months of age. Overall, it
is very likely that all three models develop a similar, mild
form of the disease, with a late (≥ 1 year) onset and a
slow progression that does not totally abolish ambulation
and sensitivity as in humans.
Whereas the rare autopsies of GAN patients have
revealed a loss of neurons in the ventral horn of the
Figure 5 Severe disorganization of cytoskeletal architecture in GAN mice. (A) Electron microscopic examination of the axoplasm of GAN
nerves revealed a diminution in microtubule content (arrows), an abnormal orientation and an increase in the diameter of neurofilaments
(individual neurofilaments indicated by an arrowhead are magnified in the inserts). (B-D) The quantification of the cytoskeletal alteration in 48
week-old GAN mice was performed in sciatic nerves, L5-ventral and dorsal roots (n = 4 mice per genotype; 4 axons per mouse; 3 random
pictures of distinct regions per axon; representing a total of 12 fields per mouse). (B) The mean number of microtubules per field was
significantly lower in GAN compared to WT nerves (*, p < 0.05, Mann-Whitney test). (C) The alteration of neurofilament orientation was assessed
by the measurement of the circularity of individual neurofilaments (circ = 1 and circ<1 representing a perfect circle and an elongated shape,
respectively). The left panel displays average circularity scores, measuring the general orientation of the neurofilaments, for individual mice in the
three tissues (the mean score per genotype is represented by a bar). The right panels show the standard deviations of the average circularity
scores for the same analysis, a measure that is representative of the variations in the orientation of individual neurofilaments within each tissue
section (*, p < 0.05, Mann-Whitney test). (D) Neurofilament diameter is significantly increased in GAN mice (10 individual neurofilaments per field;
*, p < 0.05, Mann-Whitney test).
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spinal cord [32], no motor neuron degeneration was
observed in our GANex3-5 model, in agreement with
observations in the GANex1 model at 48 weeks of age
[31]. The decrease in the axonal density in proximal and
distal nerves of our GANex3-5 129/SvJ mice was constant
but approached statistical significance and would have
required an increase in animal numbers. Nevertheless,
this observation is in accordance with the 27% axonal
loss observed in ventral roots of the GANex1 model [31].
We did not observe enlarged axons, in agreement with
both previously described models [29,31]. Thus, it
appears that gigaxonin-null mice do not mimic the axo-
nal defects that are hallmarks of human GAN, at least
at the ages that were studied. Overall, it is probable that
GAN is not fully expressed in mouse because of genic
compensation (by another E3 ligase or substrate adap-
tor), the short life span of the animals, the smaller
length of the axons or indeed environmental factors.
Regardless of the genetic background, we showed that
absence of gigaxonin in mice has a striking impact on
Figure 6 Increased abundance of NF subunits in the three GAN models. The relative increase of protein content was obtained by
comparing the mean abundance in each of the three GAN models (KO1 = our GANex3-5; KO2 = GANYY; KO3 = GANex1) with WT mice (n = 3
mice per genotype, except n = 2 for 48 week-old KO2). (A) Expression levels were quantified in the brain, the lumbar section of spinal cord (Sc-
L) and sciatic nerves (SN) by immunoblotting using anti-NFL, NFM and NFH antibodies and normalization with GAPDH antibody. (B) The relative
abundance of the gigaxonin’s partners MAP1B, MAP1S and TBCB was quantified using the corresponding antibodies, with a similar approach.
(Mann-Whitney test, *, p < 0.05; bars represent standard deviation). The immunoblots corresponding to the abundance of the NF subunits and
the gigaxonin’s partners in brain of 48 week-old GAN models are represented in (C).
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cytoskeletal architecture. Extending initial observations
[30], we reveal a significant decrease in MT content (up
to 84%) both in proximal and distal GAN nerves. It has
been proposed that the reduction of MT density could
solely result from the accumulation of the gigaxonin’s
substrate TBCB [30]. However, by quantifying its effect
in cell lines and human primary fibroblasts, we already
have shown that even in an overexpression system,
TBCB is not a potent destabilizing agent of MTs [11].
Moreover, we show here, that its abundance in the
three GAN models at different ages increases only mod-
estly in older mice, in contrary to the massive increase
that was previously reported [30]. Thus, we suggest that
TBCB accumulation might play a part in the diminution
of MT density in GAN, but that other factors such as
an alteration of the NF network are likely to be relevant.
Indeed, the most striking phenotype observed in our
GAN mouse model in both genetic backgrounds is the
broad and massive alteration of NF organization that
extends to proximal and distal nerves. Whereas NFs were
reported to be packed in the GANYY model [29], we show
here for the first time the spatial disorganization and
increased diameter of NFs, two features that are seen in
patients [4]. By evaluating the orientation of NFs by a mea-
sure of the circularity on transversal NF sections, we show
that gigaxonin-null NFs loose their parallel orientation
along the axon. Additionally, the increase of the diameter
of NFs from 9 nm in control animals to 10-12 nm in our
mice is consistent with the enlargement from 10 to 12 nm
seen in patients [4]. These alterations of NF architecture
come with a broad increase of the abundance of all NF
subunits, as reported previously in brain, cerebellum and
spinal cord tissues of GANex1 mice [31]. We show here
that the alteration in NF content is comparable in the
three GAN models, is more pronounced in the brain for all
subunits, and reaches a spectacular 4- to 7-fold increase for
NFL in 48 week-aged mice. The slight increase of NFL in
sciatic nerves is comparable to the 2-fold increase that was
revealed in the sural nerve of a patient [33]. Nevertheless,
the absence of obvious compaction of NFs in our GAN
mouse, in contrary to the 2-fold decrease in NF spacing in
patients [4,6], suggests either a milder disorganization in
rodents or reflects differences in NF architecture between
humans and mice. Interestingly, the cytoskeletal alterations
occur prior to the neuronal dysfunction (as shown by the
phenotypic deficits), allowing speculation that NF disorga-
nization may have a causative role in the development of
the mild motor and sensory deficits in our GAN mouse.
Thus, the full expression of the disease in GAN mice,
required to perform preclinical therapeutic studies,
might be achieved by exacerbation of NF collapse, by
genetically modulating NF stochiometry or by using
chemical neurotoxins [7,34] such as acrylamide, that
produces a neuropathy resembling human GAN with
accumulation of NFs [35].
Conclusions
Our results show that gigaxonin depletion in mice causes
a mild form of the GAN disease, characterized by a late
onset and a slow progression of sensory and motor symp-
toms. Nevertheless, the striking alteration of neurofila-
ment architecture in gigaxonin-null mice closely
resembles the human pathology. Indeed, the increased
abundance of neurofilaments is associated with a spatial
disorganization and an increase in diameter. Thus, our
mouse model will be useful to decipher the pathological
mechanisms by which the gigaxonin-E3 ligase maintains
neuronal survival and cytoskeletal integrity. Elucidating
the yet unknown pathological mechanisms at stake in
GAN is not only imperative for the patients, but it may
also advance our understanding of how defects of the
Ubiquitin Proteasome System and neurofilament
network, impaired in more common disorders such as
ALS, Huntington’s, Alzheimer’s and Parkinson’s diseases,
participate in neurodegeneration.
Additional material
Additional file 1: C57BL/6 GAN mice present sensory deficits. Motor
functions were evaluated with a Grip Strength test (A), and a Rotarod
test (B). Sensory deficits were recorded with a Von Frey test (C) and Hot
plate test (D). Gait analysis was assessed by a Footprint test (E). Each of
the sensory/motor tests was performed at 24, 48 and 72 weeks of age,
with additional analysis at 60 weeks of age for the Hot Plate test (n = 15
mice per genotype). The average scores, represented over time for the
Hot plate test show the statistical significance of sensory impairment in
the GAN mice from 48 weeks of age (two-way ANOVA with Bonferroni
post-test: *, p < 0,5).
Additional file 2: Lumbar motor neurons and axons are preserved
in C57BL/6 GAN mice. As described for the 129/SvJ line (see Figure 4),
the number of motor neurons (A) and distal (B) and proximal axons (C)
was determined in lumbar spinal cord, sciatic and L5 dorsal/ventral roots
sections from 48-week-old WT and GAN mice, respectively. (n = 4 per
genotype). Bars = 50 μm (A, B, C).
Additional file 3: Severe disorganization of cytoskeletal architecture
in C57BL/6 GAN mice. (A) Electron microscopic examination of the
axoplasm of GAN nerves revealed a diminution of MTs (arrows), an
abnormal orientation and an increase in the diameter of neurofilaments
(Individual Neurofilaments indicated by an arrowhead are magnified in
the inserts). (B-D) The quantification of the cytoskeletal alterations in 48
week-old GAN mice was performed as described for the 129/SvJ GAN
line (see Figure 5) in sciatic nerves, L5-ventral and dorsal roots. (*, p <
0.05, Mann-Whitney test).
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